Senior Machine Learning Scientist at Abata Therapeutics

South San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Drug DiscoveryIndustries

Requirements

PhD or equivalent practical experience in a technical field
Proven track record of developing and applying deep learning methods, including experience with modern architectures such as transformers, state-space models, graph neural networks or diffusion-based generative models
Proficiency with modern ML frameworks (e.g., PyTorch, JAX, or TensorFlow) and core scientific computing libraries (e.g., NumPy, SciPy, Pandas)
Genuine enthusiasm for applying cutting-edge ML research to real-world biological problems and a bias towards action
(Nice to Have) Prior experience with ML applied to problems in biology or chemistry
(Nice to Have) Familiarity with multimodal modeling, contrastive learning or self-supervised learning
(Nice to Have) Experience with large-scale distributed ML techniques (e.g., FSDP, TP, dMoE, flash attention)
Ability to access offices in South San Francisco, CA, or Toronto, ON (hybrid role; relocation willingness to Bay Area or Greater Toronto Area welcome)

Responsibilities

Develop and apply machine learning techniques towards building multi-modal foundation models that bridge the chemical and biological domains, i.e.: integrate models of chemical structure, target protein sequence and whole transcriptome scRNAseq
Stay at the forefront of ML and computational biology research and rapidly adopt state-of-the-art techniques to our problems and datasets
Collaborate with our team of biologists and engineers in cross-functional pods to test novel ML-driven hypotheses

Skills

PyTorch

JAX

TensorFlow

NumPy

SciPy

Pandas

Transformers

State Space Models

Graph Neural Networks

Diffusion Models

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free